Given its pathological role in PAH, PDGFR signaling has been evaluated as a therapeutic target in PAH (Barst, 2005; Perros et al., 2008a; Grimminger and Schermuly, 2010). This evidence concerns the gene PDGFRB and pulmonary arterial hypertension.